同日晚间，德福科技披露公告称，终止收购卢森堡铜箔100%股权。 公告显示，本次交易不构成关联交易，预计不构成《上市公司重大资产重组管理办法》规定的重大资产 重组。慧儒科技主要从事各类高性能电解铜箔的研发、生产和销售，主要产品包括锂电铜箔和电子电路 铜箔。截至公告披露日，慧儒科技电解铜箔产能为2万吨/年。 北京商报讯（记者 马换换 王蔓蕾）1月11日晚间，德福科技（301511）披露公告称，近日，公司与安徽 慧儒科技有限公司（以下简称"慧儒科技"）及其实际控制人王孙根签署《收购意向书》，公司拟以现金 收购及增资方式，取得慧儒科技不低于51%的股权。 ...

Core Viewpoint - The China Securities Regulatory Commission (CSRC) emphasizes the importance of risk prevention, strong regulation, and promoting high-quality development in the capital market during the 14th Five-Year Plan period [1] Group 1: Regulatory Focus - The CSRC aims to enhance the institutional environment for long-term investment and financing, focusing on improving the precision and effectiveness of services for technology innovation enterprises [1] - There is a commitment to continue promoting the value creation capabilities of listed companies and to accelerate the cultivation of top-tier investment banks and institutions [1] Group 2: Policy Implementation - The CSRC, in collaboration with various parties, has made significant progress in implementing the new "National Nine Articles" and the "1+N" policy system for the capital market [1] - Efforts are being made to increase the entry of medium- and long-term funds into the market and to strengthen support services for new productive forces [1] Group 3: Market Principles - The CSRC is dedicated to upholding the principles of fairness, openness, and transparency in the market [1]

Core Viewpoint - Wanfu Bio (300482) is expected to report its worst performance since its listing in 2015, with a projected net profit of 46 million to 69 million yuan for 2025, representing a year-on-year decline of 87.71% to 91.81% [1][5]. Financial Performance - The projected net profit for 2025 is between 46 million and 69 million yuan, marking a significant decline compared to the previous year's profit of 56,162.85 million yuan [1][5]. - The company anticipates a net profit excluding non-recurring gains and losses to be between -7.5 million and -15 million yuan, indicating a shift from profit to loss for the first time since its listing [5][6]. Business Operations - Wanfu Bio focuses on the in vitro diagnostics sector within the medical device industry, specializing in the research, production, and marketing of rapid diagnostic reagents and related instruments [5][6]. - The decline in revenue is attributed to a drop in domestic sales, influenced by VAT rate adjustments and policy impacts on hospital business, leading to pressure on both volume and pricing [6]. Market Performance - The company's stock price has underperformed, with a cumulative decline of 9.15% in 2025, while the overall market rose by 29.87% during the same period [6]. - Compared to its peak in 2020, Wanfu Bio's stock price has decreased by over 70% [6]. Future Outlook - To reverse the declining trend in performance and stock price, the company plans to focus on product specialization, cost control, channel upgrades, accelerated overseas expansion, governance optimization, and market value management [8]. - For 2026, Wanfu Bio aims to leverage market recovery, enhance its presence in grassroots healthcare, and expand its overseas market, particularly in North America, while pursuing innovation through AI applications in pathology and clinical diagnostics [8].

北京商报讯（记者 丁宁）1月11日晚间，华东医药（000963）发布公告称，公司控股子公司浙江道尔生 物科技有限公司自主研发的同类首创（FIC）的靶向成纤维细胞生长因子21受体（Fibroblast growthfactor21 receptor，FGF21R），胰高血糖素受体（Glucagon receptor，GCGR），和胰高血糖素样 肽-1受体（Glucagon-like peptide-1 receptor，GLP-1R)的长效三靶点激动剂DR10624被纳入突破性治疗品 种，拟定适应症为重度高甘油三酯血症（severe hypertriglyceridemia，sHTG）。 ...

中恒集团表示，公司将严格遵循《上海证券交易所股票上市规则》等相关规定，加快推进财务核算工 作，尽快披露2025年年度业绩预告。 北京商报讯（记者 丁宁）1月11日晚间，中恒集团（600252）发布公告称，经公司财务部门初步测算， 预计2025年年度归属净利润为负值，公司2025年年度经营业绩将出现亏损。 ...

Group 1 - The core viewpoint of the article highlights that Zhite New Materials (300986) achieved five consecutive limit-up trading days from January 5 to January 9, 2026, making it the first stock in A-shares to double in value this year [1] - On January 9, Zhite New Materials closed at the limit-up price of 27.82 yuan per share, with a total market capitalization of 11.46 billion yuan [1] - The cumulative increase in stock price from January 5 to January 9 was 148.84% [1] Group 2 - Zhite New Materials is reported as the first stock to double in value in 2026, followed by Shaoyang Hydraulic with an annual increase of 84.91% [1] - On January 8, the company disclosed an announcement regarding significant abnormal fluctuations in stock trading, confirming that there were no corrections or supplements needed for previously disclosed information [1] - The company's main business activities include the research, production, and sales of aluminum molds, protective platforms, and prefabricated components, which have not changed since its listing [1]

原本免费注册的账号昵称，如今却被玩家吐槽"千金难求""抢到怀疑人生"。 《鹅鸭杀》手游近日开启全平台公测。公开资料显示，此次官方一次性释放2000万账号池，而热门词库 仅4.6万个。 数小时后，二手平台上便出现从数十元到上千元不等的挂单。 事实上，每当热门游戏上线，职业抢注人对账号昵称抢注的现象早已不是新鲜事，平台貌似也在"默 许"这种行为。 昵称抢注乱象暴露出市场的极端供需失衡与投机炒作链条，形成零成本暴利、平台默许与法律真空下的 灰色狂欢。律师提醒消费者：如交易脱离官方渠道且昵称本身法律属性模糊，一旦发生卖家找回或官方 封禁，买家难以依据《中华人民共和国消费者权益保护法》维权，面临财物两空的风险。 挂单价最低1元、最高近万 作为曾经风靡Steam端游的爆款游戏，《鹅鸭杀》国服回归直接席卷了社交媒体。截至1月11日上午 10:30，微博上，"鹅鸭杀"话题讨论量超过128万、阅读量达18.4亿，"鹅鸭杀"相关话题达40多个。 与此同时，热门昵称如"鹅鸭杀""大司马""如花"等在1小时内被抢注一空，2000万预约玩家集体涌入导 致ID争夺激烈程度堪比"春运抢票"。 北京商报记者以消费者身份咨询某卖家，该卖家表示 ...

昵称抢注乱象暴露出市场的极端供需失衡与投机炒作链条，形成零成本暴利、平台默许与法律真空下的 灰色狂欢。律师提醒消费者：如交易脱离官方渠道且昵称本身法律属性模糊，一旦发生卖家找回或官方 封禁，买家难以依据《中华人民共和国消费者权益保护法》维权，面临财物两空的风险。 《鹅鸭杀》手游近日开启全平台公测。公开资料显示，此次官方一次性释放2000万账号池，而热门词库 仅4.6万个。 数小时后，二手平台上便出现从数十元到上千元不等的挂单。 事实上，每当热门游戏上线，职业抢注人对账号昵称抢注的现象早已不是新鲜事，平台貌似也在"默 许"这种行为。 挂单价最低1元、最高近万 作为曾经风靡Steam端游的爆款游戏，《鹅鸭杀》国服回归直接席卷了社交媒体。截至1月11日上午 10:30，微博上，"鹅鸭杀"话题讨论量超过128万、阅读量达18.4亿，"鹅鸭杀"相关话题达40多个。 该游戏幕后操盘手成都金山世游卓立科技有限责任公司（以下简称"金山世游"）相关负责人对北京商报 记者表示："IP抢注应该算是游戏行业里面比较普遍的现象，不针对《鹅鸭杀》本身。" 在上海市海华永泰律师事务所高级合伙人孙宇昊律师看来："热门游戏ID遭抢注成为普遍现 ...

原本免费注册的账号昵称，如今却被玩家吐槽"千金难求""抢到怀疑人生"。1月7日，《鹅鸭杀》手游开启全平台公测。公开资料显示，此次官方一次性释放 2000万账号池，而热门词库仅4.6万个。数小时后，二手平台上便出现从数十元到上千元不等的挂单。事实上，每当热门游戏上线，职业抢注人对账号昵称 抢注的现象早已不是新鲜事，平台貌似也在"默许"这种行为。昵称抢注乱象暴露出市场的极端供需失衡与投机炒作链条，形成零成本暴利、平台默许与法律 真空下的灰色狂欢。律师提醒消费者：如交易脱离官方渠道且昵称本身法律属性模糊，一旦发生卖家找回或官方封禁，买家难以依据《中华人民共和国消费 者权益保护法》维权，面临财物两空的风险。 挂单价最低1元、最高近万 作为曾经风靡Steam端游的爆款游戏，《鹅鸭杀》国服回归直接席卷了社交媒体。截至1月11日上午10:30，微博上，"鹅鸭杀"话题讨论量超过128万、阅读量 达18.4亿，"鹅鸭杀"相关话题达40多个。 在咸鱼平台上，"鹅鸭杀号""鹅鸭杀极品id""鹅鸭杀id"售卖贴持续上线。24小时内相关宝贝量上涨630%，但商品类目只能选"游戏账号"，平台抽佣3%，无下 架动作。 据北京商报记者不完全 ...

Core Viewpoint - Jia Mei Packaging (002969) announced that its stock will resume trading on January 12 after completing an investigation into stock price fluctuations during its suspension period [1] Group 1: Stock Performance - Jia Mei Packaging's stock price increased by 230.48% from December 17, 2025, to January 6, 2026, during which it experienced multiple instances of abnormal trading fluctuations [1] Group 2: Company Operations - The company confirmed that its production and operational activities are normal, with no significant changes in the internal or external business environment [1] - There are no undisclosed major events that could significantly impact the company's stock price [1] - The company's main business remains focused on the research, design, production, and sales of food and beverage packaging containers, as well as providing beverage filling services, with no major changes reported [1] Group 3: Future Plans - Jia Mei Packaging has no plans to change its main business operations or make significant adjustments in the next 12 months [1] - There are no plans for asset sales, mergers, joint ventures, or collaborations involving the company or its subsidiaries in the next 12 months [1] - The company does not have any plans or arrangements for a reverse merger in the next 36 months [1]